Pfizer: Macular Degeneration trials

The registry lists 17 Macular Degeneration studies with Pfizer as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 3Phase 2 3Phase 3 1Phase 4 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular DegenerationTerminatedNCT01577381Phase 2Results posted
• Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular DegenerationCompletedNCT01245387Results posted
• Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic AtrophyCompletedNCT01003691Phase 1Results posted
• Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular DegenerationCompletedNCT00877032Phase 1Results posted
• Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.CompletedNCT00858208Results posted
• Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical PracticeCompletedNCT00787319Results posted
• Macugen Observational StudyTerminatedNCT00735943Results posted
• A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.CompletedNCT00549055Results posted
• Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular DegenerationCompletedNCT00460408Results posted
• An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMDTerminatedNCT00327470Phase 4Results posted
• Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration LesionsCompletedNCT00324116Phase 4Results posted
• Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular DegenerationCompletedNCT00239928Phase 2Results posted
• A Study Of Early Markers Of Choroidal NeovascularizationTerminatedNCT00902785
• Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular DegenerationCompletedNCT00845273
• Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.WithdrawnNCT00820742
• Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)CompletedNCT00150202Phase 3
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular DegenerationTerminatedNCT00090532Phase 1/2